Reevaluation of Takhzyro^TM, (lanadelumab injection), Hereditary Angiœdema

Notice Santécom: 127169

To meet the needs of the Québec Ministry of Health and Social Services (MSSS), INESSS has developed an evaluation process for blood products with a view to their addition or refusal of their addition to Québec’s list of approved blood products (Liste des produits du système du sang du Québec).

This guidance presents the recommendation of the INESSS to add the Takhzyro™ product to the Liste des produits du système du sang du Québec for the routine prevention of hereditary angioedema (HAE) attacks in all adults and adolescents with type 1 or 2 HAE. Takhzyro™ is however not intended for the treatment of acute HAE attacks. In addition, Takhzyro™ should only be made available to Québec patients if a measure to reduce the economic burden is put in place.